Oral Ipamorelin stops at the absorption question
A gentler-sounding route is still a route that needs testing. The human papers in this file did not test a swallowed pill.
A water glass, and an untested route
Oral ipamorelin has an obvious attraction: swallowing sounds less imposing than an injection. My resistance begins when convenience is allowed to answer a question about absorption: did enough of the swallowed molecule reach blood, and did it then help?
The human pharmacokinetic study gave healthy men intravenous infusions over 15 minutes. Pharmacokinetics is the account of where a drug goes and how quickly it leaves. The bowel-surgery trial also used intravenous treatment. Neither paper establishes the absorption or benefit of oral ipamorelin in people. There is no approved oral form or published human pill test demonstrating those outcomes.
The oral versus injection question remains open after these intravenous studies. A result for swallowing still needs its own experiment.
Blood stability and digestion ask different things
The original characterization of the synthetic peptide describes the peptide’s design and acute hormone action in cells and animals. Human oral absorption remains another question. Stomach acid and digestive enzymes introduce a different problem from the one studied after a drug enters blood.
A formulation claim would need to identify what is being swallowed and show its own absorption results. Evidence about an altered compound could not settle the original peptide’s oral result simply because the two names resemble one another.
I give structural ingenuity its due, but not a free pass across that distinction. A promising design and a finished formulation are different accomplishments.
A capsule would still need patient evidence
The intravenous study found an approximately 2-hour terminal half-life and a growth-hormone pulse peaking around 40 minutes. Those timings follow intravenous administration. They cannot establish how long a pill would act, how much would be absorbed or whether it would improve sleep, strength or recovery.
The experimental amounts specify the protocols those studies tested. An oral formulation would need absorption and outcome data of its own. Changing the route also leaves FDA approval and compounding rules unresolved; no ipamorelin form has an approved medical indication.